You just read:

Preferential First-Line Use of Biogen's Tecfidera and Continued Uptake of Merck KGaA's Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year

News provided by

Spherix Global Insights

Apr 10, 2019, 03:30 ET